2019
DOI: 10.1016/j.jdcr.2019.02.006
|View full text |Cite
|
Sign up to set email alerts
|

Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
32
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 49 publications
(35 citation statements)
references
References 8 publications
(8 reference statements)
0
32
0
Order By: Relevance
“…Inhibition of this pathway with a JAK inhibitor disrupts these cytokine signals between T cells and macrophages (Figure F). Improvement in concomitant sarcoidosis has also been reported in two patients with myelodysplastic disorders treated with ruxolitinib, a JAK1 and JAK2 inhibitor, and in a third patient with sarcoidosis‐like systemic granulomatosis also treated with ruxolitinib .…”
Section: Discussionmentioning
confidence: 72%
“…Inhibition of this pathway with a JAK inhibitor disrupts these cytokine signals between T cells and macrophages (Figure F). Improvement in concomitant sarcoidosis has also been reported in two patients with myelodysplastic disorders treated with ruxolitinib, a JAK1 and JAK2 inhibitor, and in a third patient with sarcoidosis‐like systemic granulomatosis also treated with ruxolitinib .…”
Section: Discussionmentioning
confidence: 72%
“…IL-17 inhibitors have been reported to induce granulomatous inflammation in early reports. 98 JAK inhibitors have been reported in isolated case reports as beneficial for sarcoidosis, [99][100][101] as well as other granulomatous diseases, 97,[102][103][104] and offer promise as a potential emerging treatment for sarcoidosis (►Table 2).…”
Section: Tnf Inhibitorsmentioning
confidence: 99%
“…149 Four case reports of sarcoidosis patients treated with JAK inhibitors (tofacitinib or ruxolitinib) are currently available, but none of these patients had ocular involvement. [150][151][152][153] Paley et al described two patients with refractory anterior uveitis or scleritis, who could not tolerate immunosuppressants or ADA, and whose ocular disease improved upon tofacitinib treatment. 154 Nevertheless, both were treated with concurrent MTX and the specific effect of tofacitinib remains difficult to establish.…”
Section: Anti-tnf-α Treatmentmentioning
confidence: 99%